What Keraderm Treats: Main Uses and Benefits

Keraderm is a systemic therapy used for managing severe and extensive forms of psoriasis, including highly inflammatory pustular and erythrodermic variants, and chronic Disorders of Keratinization such as Ichthyoses and Darier disease. These applications address severe skin disorders when systemic support is applied when appropriate for conditions characterized by periods of heightened symptoms that are widespread, chronic, or have proven resistant to other conventional therapies.

It is applied in addressing symptoms associated with hyperkeratosis, which is the excessive thickening and hardening of the skin, and severe scaling and induration (thickness). This action supports the patient in managing symptoms related to heightened physiological activity, which generally contributes to easing the symptoms related to physical discomfort. It is commonly used to help achieve and maintain long-term, stable control in patients with chronic, recurrent skin disorders.

---

Quick Fact: Symptom Support
Symptom Domains: Relief for Severe Scaling and Hyperkeratosis
Patient Benefit: Assists with maintaining functional stability and helps patients cope more steadily with challenging, recurrent symptomatic phases.

Eligibility Scope

Category	Official Regulatory Statement
Populations for whom use is allowed	Adults are the approved age group for severe, unresponsive skin disorders. Males are permitted use under standard conditions.
Populations for whom use is not recommended	Use is not established or not recommended in pediatric patients (children/adolescents). Use is not recommended with microdosed progestin-only contraceptives.
Populations for whom use is contraindicated	Pregnant women or women intending to become pregnant for at least 3 years following discontinuation. Patients with severe hepatic impairment, severe renal impairment, chronic severe hyperlipidemia, or hypersensitivity to retinoids.

Eligibility Classifications (High-Level)

Category	Classification
Eligibility severity classification	Absolute Contraindication (Pregnancy, Severe Organ Impairment); Restricted/Conditional Use (Women of Childbearing Potential); Use Not Established (Pediatric).

Resulting Eligibility Structure

Official eligibility statements:

• Keraderm is contraindicated in women who are pregnant or who must not become pregnant for a mandatory period of 3 years after treatment cessation.
• Use is prohibited in patients with severe liver disease, severe kidney disease, or severe hyperlipidemia.
• Women of childbearing potential must strictly adhere to a Pregnancy Prevention Programme and avoid all alcohol ingestion during treatment and for 2 months after cessation.
• Blood donation is restricted during therapy and for 3 years following its completion.

Connection to the overall eligibility profile: The regulatory profile strictly limits Keraderm use due to the absolute teratogenic risk and systemic impact on the liver, kidneys, and lipids. These constraints create an explicit set of rules that prohibit use in vulnerable groups and mandate strict adherence to conditions for women of childbearing potential, allowing use primarily in adults who meet specific health and compliance criteria.

Interactions with other medicines and products

The regulatory profile for Keraderm (Acitretin) establishes multiple specific drug and substance restrictions based on documented interaction patterns.

Interaction Scope and Classification

• Medicinal Product Categories: Tetracyclines, Systemic Antipsoriatic Agents, Oral Retinoids, Microdosed Progestin Preparations, and Hydantoin Anticonvulsants are associated with documented interactions.
• Substance Interactions: Alcohol (Ethanol), Vitamin A supplements, and St. John’s Wort are cited in official interaction summaries.
• Mechanistic Basis: Interactions include pharmacokinetic conversion (Acitretin to Etretinate by Ethanol) and pharmacodynamic augmentation leading to increased risk of specific toxicities.
• Regulatory Status: Interaction severity classifications include Formally Contraindicated and Not Recommended combinations.

Official Interaction Statements

• Co-administration with Tetracyclines is formally contraindicated due to the additive risk of benign intracranial hypertension.
• Co-administration with Methotrexate is formally contraindicated due to a synergistic increase in the risk for hepatotoxicity.
• The use of Vitamin A or other oral retinoids is formally contraindicated due to the additive risk of hypervitaminosis A.
• Alcohol (Ethanol) is prohibited during therapy and for two months after in women of childbearing potential, as it induces a pharmacokinetic conversion that significantly prolongs systemic retinoid exposure.
• Microdosed progestin preparations are not recommended, as Acitretin is established to interfere with their contraceptive effect.
• Acitretin has been reported to cause a reduction in the protein binding of Phenytoin, which may alter its plasma concentration.

Connection to the Overall Interaction Profile

The drug’s interaction structure is defined by prohibitions against combinations that cause additive or synergistic organ toxicity, such as liver damage. A critical constraint is the mandatory timing rule for alcohol ingestion in the relevant population, which stems from a pharmacokinetic interaction that forms a long-acting metabolite. The overall profile focuses on mitigating these high-risk events.

Keraderm facilitates tissue repair through a multi-faceted mechanism, initiated by the structural application of a bio-absorbable keratin protein matrix. This matrix establishes a temporary three-dimensional scaffold, supporting the migration and adhesion of regenerative cells, including fibroblasts and keratinocytes, which is necessary for the initial organization of new tissue.

Simultaneously, the keratin structure modulates the local wound environment by managing exudate and acting as a decoy substrate to assist in reducing the impact of excessive Matrix Metalloproteinases (MMPs) and other destructive enzyme activity. This action influences the biological composition of the wound bed, supporting the integrity of endogenous growth factors.

Furthermore, the gradual degradation of the scaffold releases bio-active amino acids and peptides. These components serve as substrates, influencing the signaling dynamics within intracellular pathways involved in angiogenesis, cellular differentiation, and epithelialization, thereby supporting the formation of granulation tissue and the maturation of the epidermal layer.

Keraderm is a sterile, single-use, bio-absorbable keratin protein foam used as a wound dressing device. Procedural guidelines define its topical application in wound management.

Official Administration Guidelines (Topical Device)

Administration Scope	Rule
Route of Administration	Topical (External application to a wound).
Official Dosing	Supplied as sterile and for single use only.
Preparation Requirements	No pre-administration steps such as dilution or shaking are explicitly documented for the ready-to-use device.
Age/Patient Group Rules	Indicated for general wound management (no specific age-based modifications documented).
Missed-Dose Rules	Not applicable; device use is procedural and single-application based.

Required Procedural Conditions

Keraderm is indicated for the management of wounds, including partial and full thickness wounds, ulcers, and first or second-degree burns. The dressing is a bio-absorbable scaffold designed to be applied directly to the wound. The following conditions must be observed:

• The device must be applied to wounds that are classified as low to highly exuding (producing fluid).
• It is strictly contra-indicated for use on third-degree burns.
• The material is designed to be re-absorbed into the developing tissue, meaning physical removal of the foam may not be required at subsequent dressing changes.

This instruction set details the precise manner in which the sterile, keratin-based foam is applied and the conditions under which its use is permissible.

Research Evidence / Overview of Studies for Keraderm (Acitretin)

---

Evidence for Use in Severe Psoriasis

Research exploring Acitretin's role in patients studied for severe psoriasis has included Randomized Controlled Trials (RCTs), systematic reviews, and long-term observational studies. These studies primarily included adults who presented with widespread, severe forms of the condition, including both severe plaque psoriasis and the more unstable variants like generalized pustular and erythrodermic psoriasis. Researchers monitored outcomes by measuring changes in standardized tools like the Psoriasis Area and Severity Index (PASI) score and the Physician Global Assessment (PGA).

Studies describe patterns related to how symptoms evolved in the observed populations over defined time intervals, usually during short-term induction periods of 8 to 16 weeks. Findings describe patterns observed in these studies, where studies recorded measurements related to specific visual symptoms such as scaling, plaque thickness, and erythema (redness). Comparative evidence against other therapies is sometimes lacking, and consistency varies across studies, a pattern sometimes observed in early trials.

---

Evidence for Use in Chronic Keratinization Disorders

Acitretin's evaluation in rare, severe disorders of keratinization, such as Ichthyosis and Darier disease, consists primarily of open-label studies, retrospective analyses, and long-term case series. Due to the low prevalence of these conditions, large-scale RCTs are rare, and studies often feature modest sample sizes. Acitretin was evaluated in studies examining changes in the physical characteristics of the skin in both adults and pediatric patients.

Research monitored outcomes related to physical discomfort. Studies examined the physical manifestations of the disease, focusing on objective measures of Hyperkeratosis (skin thickening/hardening) and scaling. Research describes patterns related to how symptoms evolved in the observed populations over extended observation periods, often six months to one year in duration. Research provides context but not individual predictions, as findings describe group patterns derived from varied clinical settings.

---

What is Still Uncertain About the Research

Across all indications, the follow-up durations were limited in many primary controlled trials, providing less information for long-term outcomes. This limits the ability of research to describe how symptoms evolve over decades. Long-term outcomes related to durability of response and growth and development (in pediatric patients) are not fully established through controlled trials. Furthermore, comparative research is limited against some currently available systemic therapies, and evidence quality is not uniform across studies.

Key Studies & References

1. Long-term management of ichthyosis with systemic retinoids: an observational study

Common questions about Keraderm (FAQ)

Q: What is Keraderm used for?

Keraderm is a topical medicine used to treat acne vulgaris (commonly known as acne) in adults and children who are at least 9 years old.

Q: How does Keraderm work to treat acne?

Keraderm contains a retinoid known as adapalene. As a retinoid, it works primarily by influencing the growth and differentiation of skin cells. This action helps to:

• Unclog pores (follicular openings) by reducing the formation of microcomedones, the earliest stage of an acne lesion.
• Decrease inflammation associated with acne lesions (such as papules and pustules).

By normalizing the process of skin cell shedding, Keraderm helps prevent new acne lesions from forming and helps clear up existing ones.

Q: When should I apply Keraderm?

Keraderm is typically applied once daily in the evening, before bedtime, or as directed by a healthcare professional. Applying it at night can help minimize potential sun sensitivity caused by the medication.

Q: How do I apply Keraderm?

Follow these general steps when applying Keraderm:

1. Wash the affected area with a mild cleanser and gently pat it dry.
2. Apply a thin layer of Keraderm to all areas of the skin where acne lesions usually appear, not just to individual blemishes.
3. Avoid getting the medication into your eyes, nose, mouth, or on areas of cut or irritated skin.
4. Wash your hands after applying the medication.

Q: Can I use other acne products while using Keraderm?

Using Keraderm with other topical acne treatments, especially those that are peeling, drying, or abrasive (such as products containing benzoyl peroxide, sulfur, or resorcinol), may increase skin irritation. It is best to consult a healthcare professional before combining Keraderm with any other skin treatments to ensure safety and effectiveness.

Q: How long does it take for Keraderm to start working?

It can take several weeks, typically 8 to 12 weeks, of consistent use before you notice a significant improvement in your acne. It is important to continue using the medication as prescribed, even if you do not see immediate results, as the full therapeutic effect takes time.

Q: What are the common side effects of Keraderm?

The most common side effects of Keraderm, particularly during the first few weeks of use, are generally mild and localized to the treatment area. These may include:

• Redness
• Dryness
• Scaling or peeling
• Burning or stinging

These effects usually decrease after the skin adjusts to the medication. If these side effects are severe or do not improve, you should contact a healthcare professional.

Q: Is it normal for my acne to get worse when I first start using Keraderm?

Yes, some patients experience a temporary flare-up or worsening of their acne symptoms during the first few weeks of treatment. This is often an expected part of the treatment process as the medication begins to clear deeper-seated acne lesions. It usually resolves as treatment continues.

Q: Do I need to use sunscreen while using Keraderm?

Yes. Keraderm (adapalene) can make your skin more sensitive to sunlight and increase the risk of sunburn. It is essential to use a broad-spectrum sunscreen with an appropriate SPF, wear protective clothing, and limit sun exposure, including sunlamps and tanning beds, while using this medication and for a period after stopping treatment.

Keraderm (acitretin capsules) must be stored and handled according to specific regulatory standards to maintain stability and ensure safety.

Storage Conditions

Temperature and Environment: Store the capsules at controlled room temperature, 68 F to 77 F (20 C to 25 C). The medication must be protected from light, moisture, and kept from freezing . Store the product in its original closed container and strictly out of the reach of children.

Handling and Disposal

Official disposal guidelines recommend using a drug take-back program or an authorized collector for unused or expired capsules. If unavailable, mix the medication with an undesirable substance (e.g., coffee grounds) and place it in a sealed container before discarding in household trash. A critical handling requirement is that patients must not donate blood during treatment and for a mandatory 3 years after the final dose.